Dual-targeting of the aromatase binding domain of heme and androstenedione by Pt(iv) prodrugs: a new treatment for postmenopausal breast cancer

3 simultaneously occupies the heme iron-binding domain and the ASD-binding site of aromatase by a highly efficient dual-binding pattern to aromatase, exerting synergistic antitumor action of cisplatin and aminoglutethimide with low-toxicity.